Natamycin (natamycin ophthalmic)

Natamycin (natamycin ophthalmic) is filed as Ophthalmic Antifungal. The sections below restate public label fields stored for this profile.

Class
Ophthalmic Antifungal
Generic name
natamycin ophthalmic
Route
OPHTHALMIC
Dosage forms
HOW SUPPLIED: NATACYN™ (natamycin ophthalmic suspension) 5% is a 15 mL fill packaged in a 15 mL amber glass bottle with a black closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing. 15 mL NDC 82667-012-05 STORAGE: Store between 2°C to 24°C (36°F-75°F). Do not freeze . Avoid exposure to light and excessive heat. Rx Only
Manufacturer
Harrow Eye, LLC

Approved uses

INDICATIONS AND USAGE: NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established.

How it works

CLINICAL PHARMACOLOGY: Natamycin is a tetraene polyene antibiotic derived from Streptomyces natalensis . It possesses in vitro activity against a variety of yeast and filamentous fungi, including Candida, Aspergillus, Cephalosporium, Fusarium and Penicillium . The mechanism of action appears to be through binding of the molecule to the sterol moiety of the fungal cell membrane. The polyenesterol complex alters the permeability of the membrane to produce depletion of essential cellular constituents. Although the activity against fungi is dose-related, natamycin is predominantly fungicidal. Natamycin is not effective in vitro against gram-positive or gram-negative bacteria. Topical administration appears to produce effective concentrations of natamycin within the corneal stroma but not in intraocular fluid. Systemic absorption should not be expected following topical administration of NATACYN™ (natamycin ophthalmic suspension) 5%. As with other polyene antibiotics, absorption from the gastrointestinal tract is very poor. Studies in rabbits receiving topical natamycin revealed no measurable compound in the aqueous humor or sera, but the sensitivity of the measurement was no greater than 2 mg/mL.

Warnings and precautions

Information for Patients: Do not touch dropper tip to any surface, as this may contaminate the suspension. Patients should be advised not to wear contact lenses if they have signs and symptoms of fungal blepharitis, conjunctivitis, and keratitis.

Contraindications

CONTRAINDICATIONS: NATACYN™ (natamycin ophthalmic suspension) 5% is contraindicated in individuals with a history of hypersensitivity to any of its components.

Adverse reactions

The following events have been identified during post-marketing use of NATACYN ™ (natamycin ophthalmic suspension) 5% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to their seriousness, frequency of reporting, possible causal connection to NATACYN™ (natamycin ophthalmic suspension) 5%, or a combination of these factors include: allergic reaction, change in vision, chest pain, corneal opacity, dyspnea, eye discomfort, eye edema, eye hyperemia, eye irritation, eye pain, foreign body sensation, parethesia, and tearing.

Dosage and administration

DOSAGE AND ADMINISTRATION: SHAKE WELL BEFORE USING. The preferred initial dosage in fungal keratitis is one drop of NATACYN™ (natamycin ophthalmic suspension) 5% instilled in the conjunctival sac at hourly or two-hourly intervals. The frequency of application can usually be reduced to one drop 6 to 8 times daily after the first 3 to 4 days. Therapy should generally be continued for 14 to 21 days or until there is resolution of active fungal keratitis. In many cases, it may be helpful to reduce the dosage gradually at 4 to 7 day intervals to assure that the replicating organism has been eliminated. Less frequent initial dosage (4 to 6 daily applications) may be sufficient in fungal blepharitis and conjunctivitis.

Common questions

What is Natamycin approved to treat?

According to its FDA label, Natamycin (natamycin ophthalmic) is approved for: INDICATIONS AND USAGE: NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and su… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Natamycin?

Natamycin (natamycin ophthalmic) belongs to the Ophthalmic Antifungal class of medications.

What form does Natamycin come in?

The FDA label lists Natamycin (natamycin ophthalmic) as: HOW SUPPLIED: NATACYN™ (natamycin ophthalmic suspension) 5% is a 15 mL fill packaged in a 15 mL amber glass bottle with a black closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately in a clear plastic blister with Tyvek backing. 15 mL NDC 82667-012-05 STORAGE: Store between 2°C to 24°C (36°F-75°F). Do not freeze . Avoid exposure to light and excessive heat. Rx Only; ophthalmic route. Available strengths and packaging vary by manufacturer.

Does Natamycin have a Boxed Warning?

Our ingest of the FDA label for Natamycin (natamycin ophthalmic) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Natamycin cost?

Public CMS NADAC pricing for Natamycin (natamycin ophthalmic) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Natamycin currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Natamycin (natamycin ophthalmic) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Natamycin approved by the FDA?

The FDA record lists the approval date for Natamycin (natamycin ophthalmic) as 1978-10-30.

Who makes Natamycin?

The FDA label lists Harrow Eye, LLC as a labeler/manufacturer of Natamycin (natamycin ophthalmic). Multiple firms may market generics of the same molecule.

How should Natamycin be stored?

The FDA label states: "NATACYN™ (natamycin ophthalmic suspension) 5% is a 15 mL fill packaged in a 15 mL amber glass bottle with a black closure. A flint glass dropper with a red plastic closure and a black rubber bulb are packaged separately…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…